Head-To-Head Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Atrinsic (NASDAQ:PTIX)

Atrinsic (NASDAQ:PTIX) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent recommendations and price targets for Atrinsic and Praxis Precision Medicines, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1	0	0	0	1.00
Praxis Precision Medicines	2	0	13	3	2.94

Praxis Precision Medicines has a consensus price target of $436.67, indicating a potential upside of 37.64%. Given Praxis Precision Medicines’ stronger consensus rating and higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Atrinsic.

Profitability

This table compares Atrinsic and Praxis Precision Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Praxis Precision Medicines	N/A	-66.90%	-60.30%

Volatility and Risk

Atrinsic has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.85, suggesting that its stock price is 185% more volatile than the S&P 500.

Valuation & Earnings

This table compares Atrinsic and Praxis Precision Medicines”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53 million	($7.95)	-0.07
Praxis Precision Medicines	$8.55 million	934.68	-$182.82 million	($12.90)	-24.59

Atrinsic has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 8.0% of Atrinsic shares are held by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Praxis Precision Medicines beats Atrinsic on 8 of the 13 factors compared between the two stocks.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.